Item 5.02 - Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Directors: Compensatory Arrangements of Certain Officers.
On August 24, 2021, the Board of Directors (the "Board") of Apyx Medical
Corporation (the "Company") appointed Wendy Levine to serve as a director of the
Company, expanding its Board to eight (8) directors, effective August 25, 2021.
The Nominating and Governance Committee of the Board of Directors unanimously
recommended Ms. Levine to serve as a director. In addition to her service on the
Board, Ms. Levine will serve as a member of the Regulatory Compliance Committee.
Ms. Levine is Group President and head of the advertising business at 21GRAMS,
part of Real Chemistry, a global health innovation company, that she founded
with her partners in 2018. From 2003 to 2007, Ms. Levine worked at Johnson &
Johnson, where she served as Group Product Director in the Specialty
Pharmaceuticals Business Unit and then as Director, Stakeholder Marketing in the
Medical Device Business Unit. From 2007 to 2009, Ms. Levine held the position of
Senior Director of Marketing for the influenza portfolio at Novartis Vaccines.
From 2009 to 2014, a love for advertising brought her to the agency world, where
she rose through the ranks within account management at The Bloc. From 2014 to
2015, Ms. Levine held the role of EVP, Managing Director at McCann Health. From
2015 to 2017, she worked as Director of Client Services at GSW. Ms. Levine
received her bachelor's degree in interdisciplinary studies (economics and
Western European culture) from the University of Pittsburgh and a master's
degree in education from Beaver College (Arcadia University).
There is no arrangement or understanding between Ms. Levine and any other
persons pursuant to which Ms. Levine was elected as a director. The Company
believes that Ms. Levine is qualified to serve as a director of the Company
because of her extensive background in consumer marketing within the medical
device industry.
Ms. Levine will receive compensation as a director in accordance with the
Director Compensation Program applicable to all non-employee directors,
described in the Company's Definitive Proxy Statement filed with the U.S.
Securities and Exchange Commission on June 25, 2021.
Item 8.01. Other Events.
On August 30, 2021, the Company issued a press release announcing the
appointment of Ms. Levine as a director of the Company. A copy of the press
release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d)
Exhibit No. Description
99.1 Press release dated August 30, 2021
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses